Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT00910897 is registered in ClinicalTrials.gov with Intergroupe Francophone du Myelome as lead sponsor.

NCT NCT00910897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00910897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Intergroupe Francophone du Myelome
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2008
Completion date
Not reported
Enrollment
205 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma